Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DIAPREPP

Financiado

Cerrado

DIAbetes type 1 PRediction Early Pathogenesis and Prevention

The earliest currently identifiable process in the pathogenesis of type 1 diabetes (T1D) is the development of autoimmunity to islet beta cells in the form of autoantibodies. Hindering attempts to prevent autoimmune T1D, the aetio... ver más

31/08/2011

TUD

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

TECHNISCHE UNIVERSITAET DRESDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 11 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2011-08-31 No tenemos la información de la convocatoria

0% 77% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

11 Participantes

TUD

0.00€ | Lider

N.D. | Participante

VTT

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MIELT1D MHC Class I Expression Level in Type 1 Diabetes 119K€ Cerrado

EE-ASI Beta cell preservation via antigen specific immunotherapy in... 8M€ Cerrado

NANOBreg A new therapeutic platform based on nanotechnology to promot... 158K€ Cerrado

SAF2013-45140-R LINFOCITOS B Y T AUTOREACTIVOS EN LA DIABETES DEL TIPO 1: AN... 175K€ Cerrado

PID2021-125470OB-I00 PAPEL DE LAS ALTERACIONES DE LA PRESENTACION DE ANTIGENO MED... 169K€ Cerrado

LightCure LightCure - Light for double specificity and efficacy withou... 8M€ Cerrado

Líder del proyecto

TECHNISCHE UNIVERSITAET DRESDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The earliest currently identifiable process in the pathogenesis of type 1 diabetes (T1D) is the development of autoimmunity to islet beta cells in the form of autoantibodies. Hindering attempts to prevent autoimmune T1D, the aetiology and pathogenesis of the islet auto-immunization, including whether it is preceded by metabolic abnormalities and cell-mediated autoimmunity, is still poorly understood. To overcome this, DIAPREPP will focus on the early auto-immunization against islet antigens, in particular to disclose events preceding current autoantibody markers. The concept is that events prior to auto-immunization govern the likelihood and ‘signature’ of immunization, which in turn determines progression to disease. The overall objective is to determine mechanisms of islet autoantigen immunization. In a truly collaborative manner, and through five S/T workpackages plus three dedicated to dissemination, training, and management, DIAPREPP will 1. provide a unique set of clinical material that includes a case-control cohort representative of the world’s largest studies of pre-T1D, with follow-up and samples from birth, and pancreatic islets and lymph nodes from patients; 2. investigate the effects of environmental exposure to infections on islet cells and immune cells; 3. perform extensive metabolomic analysis of pre-autoimmune samples and in relevant animal models to test mechanistic hypotheses of auto-immunization; 4. carry out detailed analyses of early autoimmune responses with a special focus on autoreactive CD8+ T cells; and 5. apply findings to ongoing prevention studies. The expected impact of DIAPREPP is new fundamental knowledge regarding how 1. immunization against islet autoantigens can occur; 2. signs of self-immunization can be exploited for prediction and monitoring of disease; and 3. the immunization or its progression to islet beta cell destruction and T1D development can be prevented.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores